GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kolon Life Science Inc (XKRX:102940) » Definitions » Change In Receivables

Kolon Life Science (XKRX:102940) Change In Receivables : ₩-10,905 Mil (TTM As of Dec. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Kolon Life Science Change In Receivables?

Kolon Life Science's change in receivables for the quarter that ended in Dec. 2024 was ₩-8,240 Mil. It means Kolon Life Science's Accounts Receivable increased by ₩8,240 Mil from Sep. 2024 to Dec. 2024 .

Kolon Life Science's change in receivables for the fiscal year that ended in Dec. 2024 was ₩-10,905 Mil. It means Kolon Life Science's Accounts Receivable increased by ₩10,905 Mil from Dec. 2023 to Dec. 2024 .

Kolon Life Science's Accounts Receivable for the quarter that ended in Dec. 2024 was ₩36,699 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Kolon Life Science's Days Sales Outstanding for the three months ended in Dec. 2024 was 71.45.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Kolon Life Science's liquidation value for the three months ended in Dec. 2024 was ₩-206,839 Mil.


Kolon Life Science Change In Receivables Historical Data

The historical data trend for Kolon Life Science's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kolon Life Science Change In Receivables Chart

Kolon Life Science Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6,534.89 2,985.87 -10,333.26 4,135.82 -10,905.22

Kolon Life Science Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3,380.26 -7,098.56 -1,395.76 5,829.02 -8,239.92

Kolon Life Science Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-10,905 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kolon Life Science  (XKRX:102940) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Kolon Life Science's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=36699.358/46866.296*91
=71.45

2. In Ben Graham's calculation of liquidation value, Kolon Life Science's accounts receivable are only considered to be worth 75% of book value:

Kolon Life Science's liquidation value for the quarter that ended in Dec. 2024 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=12498.385-270225.117+0.75 * 36699.358+0.5 * 46726.483
=-206,839

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kolon Life Science Change In Receivables Related Terms

Thank you for viewing the detailed overview of Kolon Life Science's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Kolon Life Science Business Description

Traded in Other Exchanges
N/A
Address
110, Magokdong-ro, Gangseo-gu, One & Only Tower, Seoul, KOR
Kolon Life Science Inc develops, manufactures and sells Biopharmaceuticals, Active pharmaceutical ingredients, Antimicrobials and Water solutions. Its products include Invossa, KLS-1010, KLS-2020, Azilsartan, Besfloc etc. The company has manufacturing facilities in Chungju, Eumsung and Kimchun.

Kolon Life Science Headlines

No Headlines